Drawing for HELIX BIOTECH

USPTO serial 97792209

HELIX BIOTECH

Reviewed by CopyMark Law Group

Status 601
Filing date
Status date
Registration date
—
Examiner
BELL, MARLENE D
Law office
TMO LAW OFFICE 118

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with HELIX BIOTECH?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Wade R. Orr

Wade R. Orr Luedeka Neely, P.C.P.O. Box 1871Knoxville, TN 37901United States

Goods and services

ClassDescriptionStatusFirst use
042Chemical analysis; Chemical analysis services; Chemical research and analysis; Chemical, biochemical, biological and bacteriological research and analysis; Clinical research in the field of Lipid Nanoparticles, Liposomes, and Hybrid Nanoparticles; Pharmaceutical product evaluation; Pharmaceutical products development; Pharmaceutical research and development; Pharmaceutical research services; Product development; Product development and engineering services for others; Product development consultation; Product development consulting in the field of Lipid Nanoparticles (LNPs) and Liposome Samples. LNP and Liposome Formulation, Manufacturing, and Analytical Services; Product development for others; Product research and development; Basic and clinical research in the field of respiratory science and medicine; Consulting services for others in the field of design, planning, and implementation project management of Lipid Nanoparticles, Liposomes, and Hybrid Nanoparticles; Consulting services in the field of product design and development; Design and testing for new product development; Executing of chemical analyses; Medical and scientific research, namely, conducting clinical trials for others; Performance of chemical analyses; Providing a web site featuring technology enabling physicians to access resources in clinical medicine; Providing a website featuring educational information in the field of clinical research; Providing information on clinical studies via an interactive website; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing reagent sample testing and diagnostic services for others for scientific research purposes; Scientific research in the nature of conducting clinical trials for others; Scientific research in the nature of conducting clinical trials for others in the field of Lipid Nanoparticles, Liposomes, and Hybrid Nanoparticles; Testing, analysis and evaluation of leaf and petiole samples; Working on and evaluation of chemical analysesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 23, 2026MAB1ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT—
Jul 23, 2026ABN1ABANDONMENT - EXPRESS MAILED—
Jul 22, 2026EXARTEAS EXPRESS ABANDONMENT RECEIVED—
May 23, 2026RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Aug 20, 2025RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Aug 19, 2025RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Feb 18, 2025RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Jan 24, 2025RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Apr 15, 2024GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Apr 15, 2024GNSLLETTER OF SUSPENSION E-MAILED—
Apr 15, 2024CNSLSUSPENSION LETTER WRITTEN—
Feb 12, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 12, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 12, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 8, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 8, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 8, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Nov 15, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 15, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 15, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 10, 2023DOCKASSIGNED TO EXAMINER—
Mar 3, 2023MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Mar 2, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 16, 2023NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance